| Cardiovascular Diseases
Synjardy vs Crestor
Side-by-side clinical, coverage, and cost comparison for cardiovascular diseases.Deep comparison between: Synjardy vs Crestor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCrestor has a higher rate of injection site reactions vs Synjardy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Crestor but not Synjardy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Synjardy
Crestor
At A Glance
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Oral
Once daily
HMG-CoA reductase inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
- Cardiovascular Diseases
- Hyperlipidemia
- Atherosclerosis
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
Dosing
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Hyperlipidemia, Atherosclerosis, Hypertriglyceridemia 5-40 mg orally once daily in adults.
Hypercholesterolemia, Familial HeFH: 5-10 mg once daily (ages 8 to <10 years) or 5-20 mg once daily (ages 10+); HoFH: 20 mg once daily (ages 7+); adults: 5-40 mg once daily.
Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or any excipient in CRESTOR
Adverse Reactions
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Most common (>=2%) headache, nausea, myalgia, asthenia, constipation, arthralgia, dizziness, increased CPK, abdominal pain, diabetes mellitus
Serious myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria, hematuria, increases in HbA1c and fasting serum glucose
Postmarketing thrombocytopenia, hepatitis, jaundice, hepatic failure, peripheral neuropathy, cognitive impairment, myasthenia gravis, depression, sleep disorders, gynecomastia, interstitial lung disease, DRESS, lichenoid drug eruption
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
CRESTOR (rosuvastatin) is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor); inhibition accelerates hepatic LDL-receptor expression, reducing plasma LDL-C, total cholesterol, and VLDL levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Crestor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Crestor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Crestor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Synjardy.
No savings programs available for Crestor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SynjardyView full Synjardy profile
CrestorView full Crestor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.